With new $106M crossover round, Tenaya preps heart failure programs for the clinic — and maybe an IPO
Less than a year and a half since pulling in its last round of funding, Tenaya Therapeutics is back with a crossover round that could …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
